Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies

BACKGROUND: CTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire. We have previously reported clinical trials combining CTLA-4 blockade with granulocyte-macrophage colony-stimulating fa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Cham, Jason, Zhang, Li, Kwek, Serena, Paciorek, Alan, He, Tao, Fong, Grant, Oh, David Y, Fong, Lawrence
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2020
Schlagworte:
Clinical/Translational Cancer Immunotherapy
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7223469/
https://ncbi.nlm.nih.gov/pubmed/32376721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000368
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge